Merz North America announced that the FDA has approved Naftin (naftifine HCl) Gel 2% for the treatment of interdigital-type tinea pedis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum.

RELATED: Dermatological Disorders Resource Center

Clinical data from two trials (N=1,715) showed that patients treated with Naftin Gel 2% experienced clinically significant cure rates when compared to placebo. In addition, patients experienced continuous improvement in post-treatment efficacy for up to four weeks after treatment regimen had ended.

Naftin is already available in a 1% strength cream and gel indicated for the treatment of tinea pedis, tinea cruris, and tinea corporis infections.


Continue Reading

Naftin Gel 2% will be available in the fall of 2013.

For more information call (888) MERZ-USA or visit Naftin.com